Document is current
Any future updates will be listed below
-
Authors
C. Munoz Pareja, Jennifer
Mateo Chavez, Maria B.
Bernal, Julia Alexis
Swaby, Kathryn
Machado, Natalie
Pringle, Charlene
Guthrie, Kourtney
Coto, Jennifer
Rajderkar, Dhanashree
Gober, Joslyn
Solano, Juan
McCrea, Heather J.
Gonzalez Mosquera, Daniel
Alkhachroum, Ayham
O’Phelan, Kristine H.
Kobeissy, Firas
Keane, Robert W.
Wang, Kevin K.
Dietrich, W. Dalton
de Rivero Vaccari, Juan Pablo
- License Information
-
More Information
Article History
Received: 13 September 2024
Revised: 18 July 2025
Accepted: 31 July 2025
First Online: 26 September 2025
Competing interests
: K.K. Wang reported receiving personal fees as a shareholder of Gryphon Bio Inc. and Banyan Biomarkers outside of the submitted work. J.P. de Rivero Vaccari, WD Dietrich, and R.W. Keane are co-founders and managing members of InflamaCORE, LLC, and have licensed patents on inflammasome proteins as biomarkers of injury and disease, as well as on targeting inflammasome proteins for therapeutic purposes. J.C. Munoz Pareja has licensed patents on inflammasome proteins as biomarkers of injury and disease, as well as on targeting inflammasome proteins for therapeutic purposes. J.P. de Rivero Vaccari, W.D. Dietrich, and R.W. Keane are Scientific Advisory Board Members of ZyVersa Therapeutics. None of the remaining authors report interests to disclose.
: We obtained approval from the ethical standards committees at the University of Florida (IRB201600237) and the University of Miami (IRB20210352) Institutional Review Boards. We obtained written consent from participants, controls, or their legal representatives to collect blood samples and data from electronic health records (EHR). Modifications to the informed consent process at the University of Florida permitted written consent from participants, controls, or their legal representatives within 72 h of admission. At the University of Miami, we collected blood samples only after previous consent.
